Cue Biopharma Presents New Data From Phase 1 Trials Of CUE-101 In Head and Neck Cancer And CUE-102 In Wilms' Tumor 1 Positive Cancers At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
Cue Biopharma (NASDAQ:CUE) has presented positive data from its Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer's 38th Anniversary Annual Meeting. The trials showed promising results in treating head and neck cancer and Wilms' Tumor 1 positive cancers. The company reported an overall response rate of 47% and disease control rate of 65% in patients treated with CUE-101 and KEYTRUDA. The median overall survival of patients treated with CUE-101 monotherapy was 20.8 months, significantly higher than the historical average of eight months. CUE-102 also showed promising results with a disease control rate of 75%-80% at the 4mg/kg and 2mg/kg doses.
November 03, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cue Biopharma's positive results from its Phase 1 trials of CUE-101 and CUE-102 could potentially boost investor confidence and positively impact the company's stock price in the short term.
The positive results from the Phase 1 trials of CUE-101 and CUE-102 indicate that Cue Biopharma is making significant progress in its cancer research. This could potentially attract more investors, leading to an increase in demand for the company's stock and subsequently, a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100